Arvinas Q3 revenue drops sharply on lower milestone payments

What happened

Arvinas, a US biotech firm, reported Q3 revenue of $500,000, down sharply from a year earlier because it did not receive milestone and collaboration payments booked in the prior year. Its net loss widened while operating expenses fell.

Confirmed

Global impact / market context

Lower revenue with a wider net loss shows the company is not yet earning enough from its drug programs to cover costs, so it depends on its cash reserves. Management expects those reserves to fund operations into the second half of 2028, giving investors a visible deadline.

Analyst inference

Analysts rate the shares a buy on average, split between 7 buy or strong buy and 8 hold ratings, with no sells. The median 12-month price target of $14.00 sits about 86.2% above the November 2 closing price of $7.52.

Analyst inference

What to watch

1. The company expects its cash reserves to fund operations into the second half of 2028. Investors should track whether spending on the vepdegestrant program and staffing keeps that runway intact or shortens it. Confirmed
2. Watch whether new milestone or collaboration payments arrive in coming quarters, since their absence drove the revenue drop. A new partnership deal would restore a revenue stream the company currently lacks. Proposed
3. Because revenue is minimal and losses persist, future funding may depend on partnerships or raising new money, which can dilute existing shareholders. Falling research spending on vepdegestrant may signal a shift in program priorities. Analyst inference

Evidence

• Original source link unavailable